1 Laperrousaz S, Drepper VJ. [Overview of peritoneal dialysis]. Rev Med Suisse. 2016;12(507):408–12.
2 Schneider M, Pruijm M, Halabi G. [Peritoneal dialysis: what the general practitioner should know about peritoneal dialysis]. Rev Med Suisse. 2020;16(683):390–4.
3 Li PK, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. Perit Dial Int. 2016;36(5):481–508.
4 Vakilzadeh N, Burnier M, Halabi G. [Infectious peritonitis in peritoneal dialysis: an over-emphasized complication]. Rev Med Suisse. 2013;9(375):446–50.
5 Szeto CC, Li PK. Peritoneal Dialysis-Associated Peritonitis. Clin J Am Soc Nephrol. 2019;14(7):1100–5.
6 Salzer WL. Peritoneal dialysis-related peritonitis: challenges and solutions. Int J Nephrol Renovasc Dis. 2018;11:173–86.
7 Hamade A, Pozdzik A, Denis O, Tooulou M, Keyzer C, Jacobs F, et al. Mycobacterium fortuitum and Polymicrobial Peritoneal Dialysis-Related Peritonitis: A Case Report and Review of the Literature. Case Rep Nephrol. 2014;2014:323757.
8 El Helou G, Viola GM, Hachem R, Han XY, Raad, II. Rapidly growing mycobacterial bloodstream infections. Lancet Infect Dis. 2013;13(2):166–74.
9 Johansen MD, Herrmann JL, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020;18(7):392–407.
10 Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.
11 Jiang SH, Roberts DM, Dawson AH, Jardine M. Mycobacterium fortuitum as a cause of peritoneal dialysis-associated peritonitis: case report and review of the literature. BMC Nephrol. 2012;13:35.